Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
International Journal of Colorectal Disease
Published in: International Journal of Colorectal Disease 8/2009

01-08-2009 | Original Article

Elevated expressions of MMP7, TROP2, and survivin are associated with survival, disease recurrence, and liver metastasis of colon cancer

Authors: Y. J. Fang, Z. H. Lu, G. Q. Wang, Z. Z. Pan, Z. W. Zhou, J. P. Yun, M. F. Zhang, D. S. Wan

Published in: International Journal of Colorectal Disease | Issue 8/2009

Login to get access

Abstract

Purpose

Colorectal cancer is one of the most common cancers worldwide. We tested the hypothesis that differences in the expression of certain molecular markers of colon cancer may account for different clinical outcomes.

Methods

Tissue microarray technology was used to assay the expression of 17 biological markers [β-catenin, CD44v7, c-myc, cyclin D1, estrogen receptor β, mitogen-activated protein kinase/extracellular signal-regulated kinase, maspin, matrix metalloproteinase-7 (MMP7), p53, Pin1, peroxisome proliferators-activated receptor-gamma, survivin, T cell transcription factor 4 (TCF4), transforming growth factor beta receptor II (TGFβR II), TGFβ, TROP2, and Wnt] by immunohistochemistry in 620 colon cancer patients. The Cox proportional hazards regression model was applied to analyze the lifetime data, including time to death, time to recurrence, and time to liver metastasis.

Results

All the markers were present at significantly higher expression levels in tumor specimens than in normal colonic specimens. Kaplan–Meier analysis showed that high expression of TROP2, MMP7, and survivin were related to decreased survival; TCF4 and TROP2 were related to disease recurrence; and CD44v7, cyclin D1, MMP7, p53, survivin, and TCF4 were related to liver metastasis. However, the results of the multivariate analysis only showed that expression of MMP7, survivin, and TROP2 were significant predictors of lower patient survival, while TROP2 and MMP7 were significantly related to disease recurrence and liver metastasis, respectively.

Conclusions

We conclude that elevated survivin, MMP7, and TROP2 expression levels are related to decreased survival. In addition, elevated MMP7 and TROP2 expression levels are predictors of disease recurrence and liver metastasis, respectively.
Literature
1.
Weitz J, Koch M, Debus J, Hohler T, Galle PR, Buchler MW (2005) Colorectal cancer. Lancet 365:153–165PubMedCrossRef
2.
Graziano F, Cascinu S (2003) Prognostic molecular markers for planning adjuvant chemotherapy trials in Dukes' B colorectal cancer patients: how much evidence is enough? Ann Oncol 14:1026–1038PubMedCrossRef
3.
McLeod HL, Murray GI (1999) Tumour markers of prognosis in colorectal cancer. Br J Cancer 79:191–203PubMedCrossRef
4.
Leichman CG (2001) Predictive and prognostic markers in gastrointestinal cancers. Curr Opin Oncol 13:291–299PubMedCrossRef
5.
Eschrich S, Yang I, Bloom G, Kwong KY, Boulware D, Cantor A et al (2005) Molecular staging for survival prediction of colorectal cancer patients. J Clin Oncol 23:3526–3535PubMedCrossRef
6.
Kuramochi J, Arai T, Ikeda S, Kumagai J, Uetake H, Sugihara K (2006) High Pin1 expression is associated with tumor progression in colorectal cancer. J Surg Oncol 94:155–160PubMedCrossRef
7.
Kirimlioglu H, Kirimlioglu V, Yilmaz S, Sagir V, Coban S, Turkmen E et al (2006) Role of matrix metalloproteinase-7 in colorectal adenomas. Dig Dis Sci 51:2068–2072PubMedCrossRef
8.
Ponnelle T, Chapusot C, Martin L, Bouvier AM, Plenchette S, Faivre J et al (2005) Cellular localisation of survivin: impact on the prognosis in colorectal cancer. J Cancer Res Clin Oncol 131:504–510PubMedCrossRef
9.
Ohmachi T, Tanaka F, Mimori K, Inoue H, Yanaga K, Mori M (2006) Clinical significance of TROP2 expression in colorectal cancer. Clin Cancer Res 12:3057–3063PubMedCrossRef
10.
Horvath L, Henshall S (2001) The application of tissue microarrays to cancer research. Pathology 33:125–129PubMedCrossRef
11.
12.
Iczkowski KA, Omara-Opyene AL, Kulkarni TR, Pansara M, Shah GV (2005) Paracrine calcitonin in prostate cancer is linked to CD44 variant expression and invasion. Anticancer Res 25:2075–2083PubMed
13.
Chang AJ, Song DH, Wolfe MM (2006) Attenuation of peroxisome proliferator-activated receptor gamma (PPARgamma) mediates gastrin-stimulated colorectal cancer cell proliferation. J Biol Chem 281:14700–14710PubMedCrossRef
14.
Ishikawa T, Ichikawa Y, Mitsuhashi M, Momiyama N, Chishima T, Tanaka K et al (1996) Matrilysin is associated with progression of colorectal tumor. Cancer Lett 107:5–10PubMedCrossRef
15.
Hipfner DR, Cohen SM (2004) Connecting proliferation and apoptosis in development and disease. Nat Rev Mol Cell Biol 5:805–815PubMedCrossRef
16.
Fu M, Wang C, Li Z, Sakamaki T, Pestell RG (2004) Minireview: cyclin D1: normal and abnormal functions. Endocrinology 145:5439–5447PubMedCrossRef
17.
Fornaro M, Dell'Arciprete R, Stella M, Bucci C, Nutini M, Capri MG et al (1995) Cloning of the gene encoding Trop-2, a cell-surface glycoprotein expressed by human carcinomas. Int J Cancer 62:610–618PubMedCrossRef
18.
Umekita Y, Souda M, Yoshida H (2006) Expression of maspin in colorectal cancer. In Vivo 20:797–800PubMed
19.
Boltze C (2005) Loss of maspin is a helpful prognosticator in colorectal cancer: a tissue microarray analysis. Pathol Res Pract 200:783–790PubMedCrossRef
20.
Massague J, Blain SW, Lo RS (2000) TGFb signaling in growth control, cancer, and heritable disorders. Cell 103:295–309PubMedCrossRef
21.
22.
Campbell-Thompson M, Lynch IJ, Bhardwaj B (2001) Expression of estrogen receptor (ER) subtypes and ERbeta isoforms in colon cancer. Cancer Res 61:632–640PubMed
23.
Konstantinopoulos PA, Kominea A, Vandoros G, Sykiotis GP, Andricopoulos P, Varakis I et al (2003) Oestrogen receptor β (ERbeta) is abundantly expressed in normal colonic mucosa, but declines in colon denocarcinoma paralleling the tumour’s dedifferentiation. Eur J Cancer 39:1251–1258PubMedCrossRef
24.
25.
26.
Thompson N, Lyons J (2005) Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery. Curr Opin Pharmacol 5:350–356PubMedCrossRef
27.
Greene FL, Page DL, Fleming ID et al (2002) AJCC: cancer staging handbook: from the AJCC cancer staging manual, 6th edn. Springer, New York
28.
Sobin LH, Wittekind C (eds) (2002) UICC: TNM classification of malignant tumours. Wiley, London
29.
Schraml P, Kononen J, Bubendorf L, Moch H, Bissig H, Nocito A et al (1999) Tissue microarrays for gene amplification surveys in many different tumor types. Clin Cancer Res 5:1966–1975PubMed
30.
Mucci NR, Akdas G, Manely S, Rubin MA (2000) Neuroendocrine expression in metastatic prostate cancer: evaluation of high throughput tissue microarrays to detect heterogeneous protein expression. Hum Pathol 31:406–414PubMedCrossRef
31.
Richter J, Wagner U, Kononen J, Fijan A, Bruderer J, Schmid U et al (2000) High-throughput tissue microarray analysis of cyclin E gene amplification and overexpression in urinary bladder cancer. Am J Pathol 157:787–794PubMed
32.
Benson AB 3rd, Schrag D, Somerfield MR, Cohen AM, Figueredo AT, Flynn PJ et al (2004) American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 22:3408–3419PubMedCrossRef
33.
Johnson PM, Porter GA, Ricciardi R, Baxter NN (2006) Increasing negative lymph node count is independently associated with improved long-term survival in stage IIIB and IIIC colon cancer. J Clin Oncol 24:3570–3575PubMedCrossRef
34.
Nakashima K, Shimada H, Ochiai T, Kuboshima M, Kuroiwa N, Okazumi S et al (2004) Serological identification of TROP2 by recombinant cDNA expression cloning using sera of patients with esophageal squamous cell carcinoma. Int J Cancer 112:1029–1035PubMedCrossRef
35.
Kanai Y, Ushijima S, Saito Y, Nakanishi Y, Sakamoto M, Hirohashi S (2001) MRNA expression of genes altered by 5-azacytidine treatment in cancer cell lines is associated with clinicopathological parameters of human cancers. J Cancer Res Clin Oncol 127:697–706PubMed
36.
Alberti S, Miotti S, Stella M, Klein CE, Fornaro M, Menard S et al (1992) Biochemical characterization of Trop-2, a cell surface molecule expressed by human carcinomas: formal proof that the monoclonal antibodies T16 and MOv-16 recognize Trop-2. Hybridoma 11:539–545PubMedCrossRef
37.
Miotti S, Canevari S, Menard S, Mezzanzanica D, Porro G, Pupa SM et al (1987) Characterization of human ovarian carcinoma-associated antigens defined by novel monoclonal antibodies with tumor-restricted specificity. Int J Cancer 39:297–303PubMedCrossRef
38.
Fradet Y, Cordon-Cardo C, Thomson T, Daly ME, Whitmore WF Jr, Lloyd KO et al (1984) Cell surface antigens of human bladder cancer defined by mouse monoclonal antibodies. Proc Natl Acad Sci U S A 81:224–228PubMedCrossRef
39.
Lipinski M, Parks DR, Rouse RV, Herzenberg LA (1981) Human trophoblast cell-surface antigens defined by monoclonal antibodies. Proc Natl Acad Sci U S A 78:5147–5150PubMedCrossRef
40.
White PS, Forus A, Matise TC, Schutte BC, Spieker N, Stanier P et al (1999) Report of the fifth international workshop on human chromosome 1 mapping 1999. Cytogenet Cell Genet 87:143–171PubMedCrossRef
41.
El Sewedy T, Fornaro M, Alberti S (1998) Cloning of the murine TROP2 gene: conservation of a PIP2-binding sequence in the cytoplasmic domain of TROP-2. Int J Cancer 75:324–330PubMedCrossRef
42.
Suzuki A, Hayashida M, Ito T, Kawasaki H, Nakano T, Miura M et al (2000) Survivin initiates cell cycle entry by the competitive interaction with Cdk4/p16(INK4a) and Cdk2/cyclin E complex activation. Oncogene 19:3225–3234PubMedCrossRef
43.
Sarela AI, Macadam RC, Farmery SM, Markham AF, Guillou PJ (2000) Expression of the antiapoptosis gene, survivin, predicts death from recurrent colorectal carcinoma. Gut 46:645–650PubMedCrossRef
44.
Rodel F, Hoffmann J, Grabenbauer GG, Papadopoulos T, Weiss C, Gunther K et al (2002) High survivin expression is associated with reduced apoptosis in rectal cancer and may predict disease-free survival after preoperative radiochemotherapy and surgical resection. Strahlenther Onkol 178:426–435PubMedCrossRef
45.
Rodel F, Hoffmann J, Distel L, Herrmann M, Noisternig T, Papadopoulos T et al (2005) Survivin as a radioresistance factor, and prognostic and therapeutic target for radiotherapy in rectal cancer. Cancer Res 65:4881–4887PubMedCrossRef
46.
Ryan BM, Konecny GE, Kahlert S, Wang HJ, Untch M, Meng G et al (2006) Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1. Ann Oncol 17:597–604PubMedCrossRef
47.
Kato J, Kuwabara Y, Mitani M, Shinoda N, Sato A, Toyama T et al (2001) Expression of survivin in esophageal cancer: correlation with the prognosis and response to chemotherapy. Int J Cancer 95:92–95PubMedCrossRef
48.
Takai N, Miyazaki T, Nishida M, Nasu K, Miyakawa I (2002) Survivin expression correlates with clinical stage, histological grade, invasive behavior and survival rate in endometrial carcinoma. Cancer Lett 184:105–116PubMedCrossRef
49.
50.
51.
Yang D, Welm A, Bishop JM (2004) Cell survival in the absence of survivin. Proc Natl Acad Sci U S A 101:15100–15105PubMedCrossRef
52.
Okada H, Mak TW (2004) Pathways of apoptotic and nonapoptotic death in tumour cells. Nat. Rev. Cancer 4:592–603PubMedCrossRef
53.
Kawasaki H, Toyoda M, Shinohara H, Okuda J, Watanabe I, Yamamoto T et al (2001) Expression of survivin correlates with apoptosis, proliferation and angiogenesis during human colorectal carcinogenesis. Cancer 91:2026–2032PubMedCrossRef
54.
Blanc-Brude OP, Mesri M, Wall NR, Plescia J, Dohi T, Altieri DC (2003) Therapeutic targeting of the survivin pathway in cancer: initiation of mitochondrial apoptosis and suppression of tumor-associated angiogenesis. Cancer Res 9:2683–2692
55.
Ambrosini G, Adida C, Altieri DC (1997) A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3:917–921PubMedCrossRef
56.
Sternlicht MD, Werb Z (2001) How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 17:463–516PubMedCrossRef
57.
Vihinen P, Kahari VM (2002) Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. Int J Cancer 99:157–166PubMedCrossRef
58.
Gu ZD, Li JY, Li M, Gu J, Shi XT, Ke Y et al (2005) Matrix metalloproteinases expression correlates with survival in patients with esophageal squamous cell carcinoma. Am J Gastroenterol 100:1835–1843PubMedCrossRef
59.
Yamamoto H, Itoh F, Adachi Y, Fukushima H, Itoh H, Sasaki S et al (1999) Messenger RNA expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human hepatocellular carcinoma. Jpn J Clin Oncol 29:58–62PubMedCrossRef
60.
Yamashita K, Azumano I, Mai M, Okada Y (1998) Expression and tissue localization of matrix metalloproteinase 7 (matrilysin) in human gastric carcinomas. Implications for vessel invasion and metastasis. Int J Cancer 79:187–194PubMedCrossRef
61.
Leeman MF, Curran S, Murray GI (2003) New insights into the roles of matrix metalloproteinases in colorectal cancer development and progression. J Pathol 201:528–534PubMedCrossRef
62.
Crawford HC, Fingleton BM, Rudolph-Owen LA, Goss KJ, Rubinfeld B, Polakis P et al (1999) The metalloproteinase matrilysin is a target of beta-catenin transactivation in intestinal tumors. Oncogene 18:2883–2891PubMedCrossRef
63.
Zeng ZS, Shu WP, Cohen AM, Guillem JG (2002) Matrix metalloproteinase-7 expression in colorectal cancer liver metastases: evidence for involvement of MMP-7 activation in human cancer metastases. Clin Cancer Res 8:144–148PubMed
Metadata
Title
Elevated expressions of MMP7, TROP2, and survivin are associated with survival, disease recurrence, and liver metastasis of colon cancer
Authors
Y. J. Fang
Z. H. Lu
G. Q. Wang
Z. Z. Pan
Z. W. Zhou
J. P. Yun
M. F. Zhang
D. S. Wan
Publication date
01-08-2009
Publisher
Springer-Verlag
Published in
International Journal of Colorectal Disease / Issue 8/2009
Print ISSN: 0179-1958
Electronic ISSN: 1432-1262
DOI
https://doi.org/10.1007/s00384-009-0725-z

Other articles of this Issue 8/2009

International Journal of Colorectal Disease 8/2009 Go to the issue

Review

Genetics of the hamartomatous polyposis syndromes: a molecular review

Original Article

Constipation in 44 patients implanted with an artificial bowel sphincter

Original Article

Four novel germline mutations in the MLH1 and PMS2 mismatch repair genes in patients with hereditary nonpolyposis colorectal cancer

Original Article

Total mesorectal excision for rectal cancer in an unselected population: quality assessment in a low volume center

Original Article

Quality management in rectal carcinoma: what is feasible?

Original Article

ABCB1 gene polymorphisms and haplotype analysis in colorectal cancer